The consistent downregulation of activation markers following SLAMF5 blockade, particularly in MS patient-derived cells, supports the potential of SLAMF5 as a therapeutic target for modulating pathogenic myeloid cell responses in neuroinflammatory diseases such as MS. This evidence concerns the gene CD84 and myeloid sarcoma.